Norway Model Offers Key To Unlock More Complex Switches

Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.

Norway flag

Norway’s decision to switch Pfizer’s blockbuster drug Viagra from prescription-to-OTC status last month means it has joined a very select group of countries globally that have reclassified erectile dysfunction treatment sildenafil. Just Poland, New Zealand and the UK have up until now allowed sildenafil to be supplied without a prescription.

By succeeding with its Viagra switch, Pfizer became the first firm to benefit from a recent change of law in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By 

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

More from Health

International Self-Care Day: ‘Cyberchondria’ In The UK, Best Practices In The EU

 
• By 

On International Self-Care Day 2025 (July 24) PAGB releases its latest Self-Care Census which finds self-care confidence declining in the UK and AESGP launches a digital platform showcasing national-level self-care initiatives.

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

 
• By 

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.